Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
December 12, 2023 02:05 ET
|
Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
December 12, 2023 02:00 ET
|
Icosavax, Inc.
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET
|
Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Equine Healthcare Market to Cross USD 972.8 million at a CAGR of 4.3 % by 2028: Transparency Market Research Report Inc.
November 28, 2023 08:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global equine healthcare market was estimated at a value of US$ 698.7 million in 2020....
Virus-Like Particle Vaccine Market Latest Report 2023-2031 | InsightAce Analytic
November 16, 2023 02:32 ET
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Nov. 16, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Virus-Like Particle Vaccine Market- (By...
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 09, 2023 16:05 ET
|
HilleVax, Inc.
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
Hepatitis B Vaccine (Recombinant) Market Size, Market Share, Data Analysis and Forecasts, 2023-2030 | Market Study by RationalStat
November 09, 2023 08:00 ET
|
Rationalstat LLC
Wilmington, Delaware, Nov. 09, 2023 (GLOBE NEWSWIRE) -- According to RationalStat’s most recent industry analysis, the Global Hepatitis B Vaccine (Recombinant) Market value is estimated at US$ 6.5...
HilleVax to Present at Upcoming Investor Conferences
November 01, 2023 16:48 ET
|
HilleVax, Inc.
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
October 31, 2023 08:00 ET
|
Icosavax, Inc.
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda
October 19, 2023 09:16 ET
|
Sabin Vaccine Institute
WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers...